Trial Profile
Treatment of Relapsed or Refractory Neuroblastoma With Ex-Vivo Expanded and Activated Haploidentical NK Cells and Hu14.18-IL2
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 14 Sep 2022
Price :
$35
*
At a glance
- Drugs Lorukafusp alfa (Primary) ; Natural killer cell therapy (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- 12 Sep 2022 Status changed from suspended to withdrawn prior to enrolment.
- 04 Aug 2021 Planned End Date changed from 1 Sep 2021 to 1 Sep 2025.
- 04 Aug 2021 Planned primary completion date changed from 1 Sep 2021 to 1 Sep 2024.